Evidence map›Paper›PMID 33939050›Full record

ArticleAnnals of surgical oncology2021

Contralateral Suppression Index Does Not Predict Clinical Cure in Patients Undergoing Surgery for Primary Aldosteronism.

Dana A Dominguez, Praveen Chatani, Ryan Murphy, Amy R Copeland, Richard Chang, Samira M Sadowski, Fady Hannah-Shmouni, Constantine A Stratakis, Naris Nilubol

Open access · greenAbstract read
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Primary aldosteronism - a multidimensional syndrome.Nature reviews. Endocrinology · 2022
    Review
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dana A Dominguez *Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Praveen Chatani *Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ryan MurphyEndocrine Surgery Section, National Institutes of Health, Bethesda, MD, USA.
Amy R CopelandSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Richard ChangInterventional Radiology Section, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Samira M SadowskiSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Fady Hannah-ShmouniEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Constantine A StratakisEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Naris NilubolSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. naris.nilubol@nih.gov.
National Institutes of Health · USNational Cancer Institute · USNational Institutes of Health Clinical Center · US

Funding

Molecular Genetics of Endocrine Tumors and Related DisordersZIAHD008920 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATAKIS, CONSTANTINE A. · 2012 to 2021
$25.8M
Therapeutic targets and novel anticancer agents for endocrine cancersZIABC011286 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI NILUBOL, NARIS · 2010 to 2025
$16.6M
Intramural NIH HHS ZIA BC011286
6 · The paper itself

Abstract

backgroundAdrenal venous sampling (AVS) is recommended before adrenalectomy for patients with primary aldosteronism (PA) over 35 years old. The literature examining contralateral suppression (CoS) on AVS in predicting surgical outcomes is conflicting. We examined the presence of CoS in patients who underwent adrenalectomy while adjusting for clinical and biochemical factors associated with a clinical cure of hypertension (ccHTN).

methodsWe performed a retrospective review of patients with successful AVS who underwent unilateral adrenalectomy for PA at a quaternary referral center. Patients were excluded if they had overt cortisol co-secretion, or inadequate follow-up. We first evaluated the aldosterone resolution score (ARS) in predicting ccHTN in our cohort. Next, the receiver-operator characteristic analysis (ROC) was used to determine the optimal contralateral suppression index (CSI) cutoff to define CoS. We performed univariable and multivariable analyses of factors associated with ccHTN. The primary outcome was ccHTN defined as blood pressure less than 140/90 mmHg, and off blood pressure medications.

resultsOf the 102 patients on bivariable analysis, age, sex, duration of HTN, number of medications, preoperative systolic blood pressure, and creatinine level were associated with ccHTN. ROC analysis of ARS had an AUC of 0.850 (p < 0.001). On multivariable analysis, only ARS remained associated with ccHTN (OR 3.40, 95% CI 1.20-9.61, p = 0.021). CSI was not significantly associated with ccHTN on ROC, bivariable, or multivariable analyses.

conclusionThe presence of CoS was not useful in predicting ccHTN following unilateral adrenalectomy for PA in our cohort. After adjusting for clinical and biochemical factors, ARS remains a useful predictor for ccHTN.

Indexed as

HyperaldosteronismAdrenalectomyAdrenal GlandsAdultAldosteroneHumansRetrospective StudiesTreatment OutcomeAldosterone

Identifiers

PMID33939050
PMCPMC8530859
OpenAlexW3157539420

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.